MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology
NCT ID: NCT00239759
Last Updated: 2009-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2002-09-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Onset Alzheimer's Disease Genomic Study
NCT03645993
Alzheimer's Disease Genetics Study
NCT00064870
The Genetic Characterization of Dementia
NCT01867359
Investigating Genetic Status in Patients Presenting to Clinic
NCT05911932
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II
NCT00089882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The researchers are turning their attention to the growing body of evidence from pathological, epidemiological and genetic studies that risk factors for vascular disease also enhance the risk of AD. However, since most epidemiological studies lack neuroimaging data, it is unclear whether the apparent association between vascular risk factors and AD is brought about by ischemic injury to the brain, acceleration of the primary Alzheimer neurodegenerative process, or some other process.
Some vascular risk factors are more prevalent in African American and Japanese American populations than in Caucasians. This study will build upon earlier work by evaluating the association between APOE, genes involved in vascular function, and other indictors of cerebrovascular health including blood pressure and structural brain imaging (MRI), and susceptibility to AD in these ethnic groups.
In order to carry out this project successfully, a sample of 1000 patients (500 Caucasians, 300 African Americans, 200 Japanese Americans) who meet NINCDS/ADRDA criteria for probable or definite AD from 11 centers in the U.S., Canada and Germany will be recruited. Many patients will be identified from the existing family registries. Family history, medical history, and epidemiological information will be obtained from the AD patient and their first-degree relatives using standardized questionnaire instruments and established protocols. A cognitive screening test will be administered to and blood samples will be collected from the patient's living siblings, spouses and children over the age of 50 years. DNA, plasma and MRI of the brain will be evaluated in patients and siblings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Probable or definite AD by NINCDS-ADRDA criteria
* Living siblings who are cognitively normal as measured by a brief standardized cognitive assessment
* Ages 60 and over for Alzheimer's disease patients
* Ages 50 and over for cognitively normal siblings
Exclusion Criteria
* History of clinical stroke
* Siblings whose cognitive assessment does not meet study criteria
* Pacemaker or other contraindication to MRI
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lindsay Farrer, PhD
Role: PRINCIPAL_INVESTIGATOR
Chief, Genetics Program, Boston University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Sun Health Research Institute
Sun City, Arizona, United States
Rancho Los Amigos National Rehabilitation Center/University of Southern California
Downey, California, United States
University of California, Davis
Sacramento, California, United States
Howard University
Washington D.C., District of Columbia, United States
University of Miami School of Medicine
Miami Beach, Florida, United States
Morehouse School of Medicine
Atlanta, Georgia, United States
Pacific Health Research Institute
Honolulu, Hawaii, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Cornell Medical University
New York, New York, United States
Case Western Reserve University
Cleveland, Ohio, United States
University of British Columbia
Vancouver, British Columbia, Canada
Technical University of Munich
Munich, , Germany
G. Papanicolaou Hospital
Exholi Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bachman DL, Green RC, Benke KS, Cupples LA, Farrer LA; MIRAGE Study Group. Comparison of Alzheimer's disease risk factors in white and African American families. Neurology. 2003 Apr 22;60(8):1372-4. doi: 10.1212/01.wnl.0000058751.43033.4d.
Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003 May;60(5):753-9. doi: 10.1001/archneur.60.5.753.
Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA; MIRAGE Study Group. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):103-5. doi: 10.1136/jnnp.2003.024927.
Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA; MIRAGE Study Group. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr. 2005 Jan 12;5:2. doi: 10.1186/1471-2318-5-2.
Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA. APOE, vascular pathology, and the AD brain. Neurology. 2005 Jul 26;65(2):259-65. doi: 10.1212/01.wnl.0000168863.49053.4d.
Related Links
Access external resources that provide additional context or updates about the study.
Boston University Alzheimer's Disease Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2R01AG0902911-A2
Identifier Type: -
Identifier Source: secondary_id
IA0085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.